MD, PhD. Adjunct Professor, Division of Vascular and Endovascular Surgery, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil.
MD. Resident, Division of Vascular and Endovascular Surgery, Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil.
Sao Paulo Med J. 2022 Mar 14;140(2):320-327. doi: 10.1590/1516-3180.2021.0374.R2.15092021. eCollection 2022.
Congenital vascular anomalies and hemangiomas (CVAH) such as infantile hemangiomas, port-wine stains and brain arteriovenous malformations (AVMs) impair patients' lives and may require treatment if complications occur. However, a great variety of treatments for those conditions exist and the best interventions remain under discussion.
To summarize Cochrane systematic review (SR) evidence on treatments for CVAH.
Review of SRs conducted in the Division of Vascular and Endovascular Surgery of Universidade Federal de São Paulo, Brazil.
A broad search was conducted on March 9, 2021, in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed treatments for CVAH. The key characteristics and results of all SRs included were summarized and discussed.
A total of three SRs fulfilled the inclusion criteria and were presented as a qualitative synthesis. One SR reported a significant clinical reduction of skin redness by at least 20%, with more pain, among 103 participants with port-wine stains. One SR reported that propranolol improved the likelihood of clearance 13 to 16-fold among 312 children with hemangiomas. One SR reported that the relative risk of death or dependence was 2.53 times greater in the intervention arm than with conservative management, among 218 participants with brain AVMs.
Cochrane reviews suggest that treatment of port-wine stains with pulsed-dye laser improves redness; propranolol remains the best option for infantile hemangiomas; and conservative management seems to be superior to surgical intervention for treating brain AVMs.
先天性血管异常和血管畸形(CVAH),如婴儿血管瘤、葡萄酒色斑和脑动静脉畸形(AVM),会影响患者的生活,如果发生并发症可能需要治疗。然而,对于这些疾病存在着各种各样的治疗方法,最佳干预措施仍在讨论中。
总结 Cochrane 系统评价(SR)中关于 CVAH 治疗的证据。
在巴西圣保罗联邦大学血管和血管外科学系进行的 SR 综述。
于 2021 年 3 月 9 日在 Cochrane 系统评价数据库中进行了广泛的检索,以检索评估 CVAH 治疗方法的任何 Cochrane SR。总结并讨论了所有纳入的 SR 的关键特征和结果。
共有 3 项 SR 符合纳入标准,并以定性综合的形式呈现。一项 SR 报告称,103 例葡萄酒色斑患者中,至少有 20%的皮肤红斑显著减少,疼痛也有所减轻。一项 SR 报告称,普萘洛尔可使 312 例血管瘤患儿的清除率提高 13 至 16 倍。一项 SR 报告称,在 218 例脑 AVM 患者中,干预组的死亡或依赖风险是保守治疗组的 2.53 倍。
Cochrane 综述表明,脉冲染料激光治疗葡萄酒色斑可改善红斑;普萘洛尔仍然是婴儿血管瘤的最佳选择;保守治疗似乎优于手术干预治疗脑 AVM。